Forbes A 'Holy Grail' Sleep Apnea Pill Could Be On The Market Next Year
Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.
Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.